Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma [NA]

View source ↗

Summary

Clinical trial update for JY231 injection for relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• JY231 Injection

Snippet

Sponsor: He Huang | Conditions: B-Non Hodgkin Lymphoma | NA | Status: NOT_YET_RECRUITING